Discontinued Product(±)-3-(3-Nitrobenzoyl)alanine hydrochloride (Cat. No. 0799) has been withdrawn from sale for commercial reasons.
The first potent and selective inhibitor of kynurenine-3-hydroxylase. Increases the concentration of kynurenic acid in vivo.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
References are publications that support the biological activity of the product.
Carpendo et al (1994) Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities. Neuroscience 61 237 PMID: 7969905
Chiarugi and Moroni (1999) Quinolinic acid formation in immune-activated mice: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(-3-nitrophenyl)thiazol-2yl]-benzenesulfonamide. Neuropharmacology 38 1225 PMID: 10462134
Pellicciari et al (1994) Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase. J.Med.Chem. 37 647 PMID: 8126705
View Related Products by Product Action
Keywords: (±)-3-(3-Nitrobenzoyl)alanine hydrochloride, (±)-3-(3-Nitrobenzoyl)alanine hydrochloride supplier, Non-selective, Ionotropic, Glutamate, 0799, Tocris Bioscience
Citations for (±)-3-(3-Nitrobenzoyl)alanine hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for (±)-3-(3-Nitrobenzoyl)alanine hydrochloride.
Reviews for (±)-3-(3-Nitrobenzoyl)alanine hydrochloride
There are currently no reviews for this product. Be the first to review (±)-3-(3-Nitrobenzoyl)alanine hydrochloride and earn rewards!
Have you used (±)-3-(3-Nitrobenzoyl)alanine hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.